LeMaitre Vascular (NASDAQ:LMAT) Given Outperform Rating at Barrington Research

Key Points

• LeMaitre Vascular has received an "outperform" rating from Barrington Research with a price target of $95.00, indicating a potential upside of 4.01% from its previous close.
• In its latest earnings report, LeMaitre Vascular achieved $0.60 earnings per share, surpassing expectations of $0.57, and reported a 15.0% year-over-year revenue increase.
• Insider trading activity showed CEO George W. Lemaitre sold 100,000 shares for approximately $9.35 million, reducing his ownership by 5.47%.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report)'s stock had its "outperform" rating reissued by stock analysts at Barrington Research in a report released on Tuesday,Benzinga reports. They currently have a $95.00 price objective on the medical instruments supplier's stock. Barrington Research's price objective indicates a potential upside of 4.01% from the stock's previous close.

Separately, Cantor Fitzgerald lifted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $97.60.

LeMaitre Vascular Trading Down 1.0%

Shares of LMAT stock traded down $0.95 during trading hours on Tuesday, hitting $91.34. 24,131 shares of the company were exchanged, compared to its average volume of 189,578. The firm has a market cap of $2.07 billion, a PE ratio of 44.44, a PEG ratio of 2.37 and a beta of 0.79. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The firm has a fifty day moving average of $90.69 and a 200 day moving average of $86.05.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same period in the prior year, the firm posted $0.52 EPS. The company's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 100,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. This trade represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director owned 2,916 shares in the company, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock worth $11,280,206 over the last ninety days. Company insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LMAT. Parkside Financial Bank & Trust increased its position in shares of LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 287 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at $26,000. NBC Securities Inc. bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at $36,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at $47,000. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.